Abiopharma

BICARA THERAPEUTICS INC. (BCAX)

Symbol	BCAX
Name	BICARA THERAPEUTICS INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Pharmaceutical Preparations
Address	245 MAIN,STREET, CAMBRIDGE, Massachusetts, 02142, United States
Telephone	617-468-4219
Fax	—
Email	—
Website	https://www.bicara.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	—
Description	Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, or HNSCC, where there remains a significant unmet need. We intend to initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy in recurrent/metastatic HNSCC excluding HPV-positive patients with oropharyngeal squamous cell carcinoma late in the fourth quarter of 2024 or early in the first quarter of 2025. Additional info from NASDAQ: Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, or HNSCC, where there remains a significant unmet need. We intend to initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy in recurrent/metastatic HNSCC excluding HPV-positive patients with oropharyngeal squamous cell carcinoma late in the fourth quarter of 2024 or early in the first quarter of 2025.

2026-04-27 08:33

New Form DEFA14A - Bicara Therapeutics Inc. Filed: 2026-04-27 AccNo: 0001628280-26-027321 Size: 1 MB

2026-04-27 08:33

New Form DEF 14A - Bicara Therapeutics Inc. Filed: 2026-04-27 AccNo: 0001628280-26-027320 Size: 2 MB

2026-04-22 20:53

Hyep Ivan 🟡 adjusted position in 9.2K shares (1 derivative) of Bicara Therapeutics Inc. (BCAX) at $23.00 Transaction Date: Apr 21, 2026 | Filing ID: 026604

2026-04-21 20:09

📋 Hyep Ivan (Officer) plans to sell 9K shares of Bicara Therapeutics Inc. (at $23.18 each, total $213K) Filed: Apr 21, 2026 | ID: 000461

2026-04-20 23:27

Director Mazumdar Claire 🟡 adjusted position in 15.0K shares (4 derivative) of Bicara Therapeutics Inc. (BCAX) at $23.61 Transaction Date: Apr 16, 2026 | Filing ID: 026089

2026-04-20 20:02

📋 Mazumdar Claire (Officer) plans to sell 15K shares of Bicara Therapeutics Inc. (at $23.74 each, total $356K) Filed: Apr 20, 2026 | ID: 000457

2026-04-17 20:55

Director Cohlhepp Ryan 🟡 adjusted position in 12.5K shares (1 derivative) of Bicara Therapeutics Inc. (BCAX) at $23.01 Transaction Date: Apr 15, 2026 | Filing ID: 025817

2026-04-15 20:06

📋 Cohlhepp Ryan (Officer) plans to sell 12K shares of Bicara Therapeutics Inc. (at $22.98 each, total $287K) Filed: Apr 15, 2026 | ID: 000449

2026-04-08 16:26

New Form SCHEDULE 13G/A - Bicara Therapeutics Inc. Filed: 2026-04-08 AccNo: 0001897612-26-000342 Size: 7 KB

2026-04-03 12:30

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT07552558	Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for H…	Phase1	Head and Neck Squamous Cell Carcinoma	Not_Yet_Recruiting	2026-06-30	2033-08-31	ClinicalTrials.gov
NCT07529873	Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients Wit…	Phase2	Squamous Cell Carcinoma of Head and Neck (SCCHN)	Not_Yet_Recruiting	2026-05-01	2030-12-01	ClinicalTrials.gov

Total clinical trials: 2

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
Ficerafusp alfa	Other	Phase PHASE1	Head and Neck Squamous Cell Carcinoma	NOT_YET_RECRUITING	NCT07552558
Pembrolizumab	Other	Phase PHASE1	Head and Neck Squamous Cell Carcinoma	NOT_YET_RECRUITING	NCT07552558
Hypofractionated Stereotactic Body Radiotherapy (SBRT)	Drug	Phase PHASE1	Head and Neck Squamous Cell Carcinoma	NOT_YET_RECRUITING	NCT07552558
Ficerafusp alfa	Other	Phase PHASE1	Head and Neck Squamous Cell Carcinoma	NOT_YET_RECRUITING	NCT07552558
Pembrolizumab	Other	Phase PHASE1	Head and Neck Squamous Cell Carcinoma	NOT_YET_RECRUITING	NCT07552558
Hypofractionated Stereotactic Body Radiotherapy (SBRT)	Drug	Phase PHASE1	Head and Neck Squamous Cell Carcinoma	NOT_YET_RECRUITING	NCT07552558
Ficerafusp alfa	Other	Phase PHASE1	Head and Neck Squamous Cell Carcinoma	NOT_YET_RECRUITING	NCT07552558
Pembrolizumab	Other	Phase PHASE1	Head and Neck Squamous Cell Carcinoma	NOT_YET_RECRUITING	NCT07552558
Hypofractionated Stereotactic Body Radiotherapy (SBRT)	Drug	Phase PHASE1	Head and Neck Squamous Cell Carcinoma	NOT_YET_RECRUITING	NCT07552558
Ficerafusp alfa	Other	Phase PHASE1	Head and Neck Squamous Cell Carcinoma	NOT_YET_RECRUITING	NCT07552558
Pembrolizumab	Other	Phase PHASE1	Head and Neck Squamous Cell Carcinoma	NOT_YET_RECRUITING	NCT07552558
Hypofractionated Stereotactic Body Radiotherapy (SBRT)	Drug	Phase PHASE1	Head and Neck Squamous Cell Carcinoma	NOT_YET_RECRUITING	NCT07552558

Total products: 12